JuliaKatherine
@juliakatherine.bsky.social
Independent Patient/Research Advocate, Founding Member and Lead Research Advocate: Lobular Breast Cancer Alliance, Publications and Clinical Trials Curator, Patient Advisory Board #Lobular #LBCA
Thanks for spotting this @amybeumer.bsky.social. So rare to see lobular reported out in trials.
Re: SONIA results (CDK 4/6i 1st or 2nd line). Post-hoc analysis of lobular v. ductal stuck out for almost favoring 1st line in lobular. Small numbers, tight line in the forest plot --> even more intriguing. Follow up needed and/or consider this in decision making? Thoughts? #lobmob #oncsky #bcsm
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com
December 11, 2024 at 8:56 PM
Thanks for spotting this @amybeumer.bsky.social. So rare to see lobular reported out in trials.